Hypertrophic Cardiomyopathy with a Twist

Hypertrophic cardiomyopathy is a relatively common inherited cardiac disorder, with echocardiography still being the initial imaging method for its diagnosis. Cardiac fibroma is a primary neoplasm that most commonly presents in childhood. We present a patient who was investigated for typical cardiac symptoms who went on to have cardiac magnetic resonance imaging and was found to have both of these conditions.

Cardiac Disorder Classification by Electrocardiogram Sensing Using Deep Neural Network

Cardiac disease is the leading cause of death worldwide. Cardiovascular diseases can be prevented if an effective diagnostic is made at the initial stages. The ECG test is referred to as the diagnostic assistant tool for screening of cardiac disorder. The research purposes of a cardiac disorder detection system from 12-lead-based ECG Images. The healthcare institutes used various ECG equipment that present results in nonuniform formats of ECG images. The research study proposes a generalized methodology to process all formats of ECG. Single Shoot Detection (SSD) MobileNet v2-based Deep Neural Network architecture was used to detect cardiovascular disease detection. The study focused on detecting the four major cardiac abnormalities (i.e., myocardial infarction, abnormal heartbeat, previous history of MI, and normal class) with 98% accuracy results were calculated. The work is relatively rare based on their dataset; a collection of 11,148 standard 12-lead-based ECG images used in this study were manually collected from health care institutes and annotated by the domain experts. The study achieved high accuracy results to differentiate and detect four major cardiac abnormalities. Several cardiologists manually verified the proposed system’s accuracy result and recommended that the proposed system can be used to screen for a cardiac disorder.

A Comparative Study on the Carbohydrate proৎile and In-vitro Glycaemic Index of Processed Basil (Ocimum basilicum) Seeds Incorporated Idlis

The tiny black Ocimum basilicum seeds, also called as basil or sabja seeds aid to keep blood sugar levels under control by decelerating the carbohydrate conversion into glucose, a simple sugar. Raw and Steamed Ocimum basilicum seeds in the proportions of 5% (RV1, SV1), 10% (RV2, SV2), 15% (RV3, SV3) and 20% (RV4, SV4) of the black gram have been incorporated in the idli formulation. The results depicted that as the proportion of O.basilicum seeds increased the total carbohydrate and sugar values showed a decline, whereas the cellulose, hemicellulose and resistant starch values increased. At 120 minutes, the mean in vitro glycaemic index of the control idli was estimated to be 66.45 ± 0.03, while the mean estimated glycaemic index value of raw O.basilicum seed incorporated variations of idli namely RV1, RV2, RV3 and RV4 were 55.09 ± 0.02, 53.19 ± 0.02, 51.44 ± 0.01 and 48.09 ± 0.01 respectively. The mean estimated glycaemic index value of steamed O.basilicum seed incorporated variations of idli SV1 was found to be 62.72 ± 0.01, SV2 was 60.43 ± 0.01, SV3 was 58.16 ± 0.02, and SV4 was 56.63 ± 0.02 at 120 minutes. Hence it is opined that the 20% raw O.basilicum seed incorporated idli is very much low in estimated G.I values can be used in idli preparation as a means to offer a lower glycaemic index to the obese, diabetic and cardiac disorder populations.

Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers

Purpose: The purpose of this quantitative comparative study was to examine the possible relationship between nicotine replacement therapy (NRT) and cardiac disorder risk by comparing the rates of cardiac disorder risk of NRT with cardiac disorder risk of non-replacement drugs among smokers seeking smoking cessation. Methods: The study used retrospective quantitative design, which involved the collection of secondary data from the adverse event reporting system (FAERS) database of the U.S Food and Drug Administration (FDA). Rates of cardiac disorder were compared between the NRT group and non- NRT (varenicline and bupropion) group. Statistical analyses involved using a 2x2 contingency table and logistic regression to calculate odds ratio (reporting odds ratio (ROR)). Results and Discussion: Unadjusted ROR was 0.45 (95% confidence interval [CI] 0.28, 0.70). With age and sex as confounding factors, the smokers in the NRT group still had lower odds of having cardiac disorder risk than the non-NRT group (adjusted ROR=0.44, 95% CI 0.28, 0.70). Conclusion: Our study findings showed lower cardiac disorder risk with the NRT group compared to the non-NRT (varenicline and bupropion) group. While the study did not aim to undermine either using NRT or non-NRT for smoking cessation therapy to prevent smoking illness, the study results offer informed findings that could potentially improve current smoking cessation management using NRT intervention among smokers and enhance smokers’ health outcome. Despite the negative signal detection of cardiac disorder risk with NRT as compared to non-NRT in final findings, we still recommend further research on the causal relationship between NRT and non-NRT and cardiac disorder risk.

PNA-Based Graphene Oxide/Porous Silicon Hybrid Biosensor: Towards a Label-Free Optical Assay for Brugada Syndrome

Peptide nucleic acid (PNA) is a synthetic DNA mimic that outperforms the properties of traditional oligonucleotides (ONs). On account of its outstanding features, such as remarkable binding affinity towards complementary DNA or RNA as well as high thermal and chemical stability, PNA has been proposed as a valuable alternative to the ON probe in gene-sensor design. In this study, a hybrid transducer made-up of graphene oxide (GO) nano-sheets covalently grafted onto a porous silicon (PSi) matrix has been investigated for the early detection of a genetic cardiac disorder, the Brugada syndrome (BS). A functionalization strategy towards the realization of a potential PNA-based device is described. A PNA, able to detect the SCN5A gene associated with the BS, has been properly synthesized and used as a bioprobe for the realization of a proof-of-concept label-free optical PNA-biosensor. PSi reflectance and GO photoluminescence signals were simultaneously exploited for the monitoring of the device functionalization and response.

PNA-based Graphene Oxide/porous Silicon Hybrid Biosensor: Towards a Label-free Optical Assay for Brugada Syndrome

Peptide nucleic acid (PNA) is a synthetic DNA mimic that outperforms the properties of traditional oligonucleotides (ONs). On account of its outstanding features, such as remarkable binding affinity towards complementary DNA or RNA as well as high thermal and chemical stability, PNA has been proposed as a valuable alternative to the ON probe in gene-sensor design. In this study, a hybrid transducer made-up of graphene oxide (GO) nano-sheets covalently grafted onto a porous silicon (PSi) matrix has been investigated for the early detection of a genetic cardiac disorder, the Brugada syndrome (BS). A functionalization strategy towards the realization of a potential PNA-based device is described. A peptide nucleic acid (PNA), able to detect the SCN5A associated with the BS has been properly synthesized and used as a bioprobe for the realization of a proof-of-concept label-free optical PNA-biosensor. PSi reflectance and GO photoluminescence (PL) signals were simultaneously exploited for the monitoring of the device functionalization and response.